Wei Jian Tan

Wei Jian Tan

Auto-generated profile, based on publicly available information

Wei Jian Tan

East Kent Hospitals University NHS Foundation Trust

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Qingfeng ChenQingfeng Chen
Qingfeng Chen
WYWeijian Ye
Weijian Ye
WTWei Jian Tan
Wei Jian Tan
KYKylie Su Mei Yong
Kylie Su Mei Yong
MLMin Liu
Min Liu
JCJianzhu Chen
Jianzhu Chen
Understanding of natural killer (NK) cell development in human is incomplete partly because of limited access to appropriate human tissues. We have developed a cytokine-enhanced humanized mouse model with greatly improved reconstitution and function of human NK cells. Here we report the presence of a cell population in the bone marrow of the cytokine-treated humanized mice that express both NK cell marker CD56 and myeloid markers such as CD36 and CD33. The CD56+CD33+CD36+ cells are also found in human cord blood, fetal and adult bone marrow. Although the CD56+CD33+CD36+ cells do not express the common NK cell functional receptors and exhibit little cytotoxic and cytokine-producing activities, they readily differentiate into mature NK cells by acquiring expression of NK cell receptors and losing expression of the myeloid markers. Further studies show that CD33+CD36+ myeloid NK precursors are derived from granulo-myelomonocytic progenitors. These results delineate the pathway of human NK cell differentiation from myeloid progenitors in the bone marrow and suggest the utility of humanized mice for studying human hematopoiesis.

8 September 2016 in Blood
Verified
Journal Article
Closed access
JLJunyun Lai
Junyun Lai
WTWei Jian Tan
Wei Jian Tan
CTChien Tei Too
Chien Tei Too
JCJoanna Ai Ling Choo
Joanna Ai Ling Choo
LWLan Hiong Wong
Lan Hiong Wong
PMPaul A. MacAry
Paul A. MacAry
Key Points: Anti-EBV TCR-like monoclonal antibodies reduce BLCLs tumor load in vivo. Anti-EBV TCR-like monoclonal antibodies mediate phagocytosis of BLCLs by macrophages.

22 August 2019 in Blood
Verified
Journal Article
Closed access
PDF file
WTWei Jian Tan
Wei Jian Tan
MWMona Meng Wang
Mona Meng Wang
PRPaola Ricciardi-Castagnoli
Paola Ricciardi-Castagnoli
TTTiffany Tang
Tiffany Tang
SCSoon Phaik Chee
Soon Phaik Chee
Anita Sook Yee ChanAnita Sook Yee Chan
Anita Sook Yee Chan

1 July 2021 in Ophthalmology
Verified
Journal Article
Open access
WTWei Jian Tan
Wei Jian Tan
MWMona Meng Wang
Mona Meng Wang
PCPaola Ricciardi Castagnoli
Paola Ricciardi Castagnoli
TTTiffany Tang
Tiffany Tang
Anita Sook Yee ChanAnita Sook Yee Chan
Anita Sook Yee Chan
TLTong Seng Lim
Tong Seng Lim
To test whether analyzing DEPArray (Menarini Silicon Biosystems) isolated single B cells from the vitreous fluid can reveal crucial genomic and clinicopathological features to distinguish patients with vitreoretinal lymphoma (VRL) from those with chronic inflammation using immunoglobulin heavy chain (IGH), disease biomarker myeloid differentiation primary response 88 (MYD88)L265P mutation, and copy number profiling. A single-center, retrospective study. Remnant vitreous biopsies from 7 patients with VRL and 4 patients with chronic inflammation were acquired for molecular analysis. Vitreous fluid samples were prefixed in PreservCyt (Hologic) and underwent cytologic analysis and immunohistochemistry examination. Single cells were isolated using the DEPArray NxT system, followed by downstream genomic analysis. The frequencies of the dominant IGH and MYD88L265P mutation and the genome-wide copy number aberration (CNA) profiles of individual vitreous-isolated B cells were characterized. An average of 10 to 13 vitreous B cells were used in the single-cell IGH and MYD88 analyses. Higher frequencies of dominant IGH (88.8% ± 13.2%) and MYD88L265P mutations (35.0% ± 31.3%) were detected in patients with VRL than in patients with chronic inflammation (65.9% ± 13.4% and 1.5% ± 2.6% for IGH and MYD88L265P, respectively). In a cytology-proven VRL case, all 15 vitreous isolated B cells were derived from the same clone with 100% paired IGH: immunoglobulin light chain (IGK) sequences. Genome-wide copy number profiling revealed a high degree of similarity between B cells from the same patient with VRL, with extensive gains and losses at the same areas across the whole genome. In addition, 14 of 15 B cells showed a BCL2/JH t(14;18) translocation, confirming cellular malignancy with a clonal origin. Clustering analysis of the copy number profiles revealed that malignant B cells derived from different patients with VRL had no common genome-wide signatures. Single B-cell genomic characterization of the IGH, MYD88L265P mutation, and copy number profile enables VRL diagnosis. Because our study involved only a small cohort, these meaningful proof-of-concept data now warrant further investigation in a larger patient cohort.

30 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JLJunyun Lai
Junyun Lai
JCJoanna Ai Ling Choo
Joanna Ai Ling Choo
WTWei Jian Tan
Wei Jian Tan
CTChien Tei Too
Chien Tei Too
MOMin Zin Oo
Min Zin Oo
PMPaul A. MacAry
Paul A. MacAry
Epstein-Barr virus (EBV) is a common gammaherpesvirus associated with various human malignancies. Antibodies with T cell receptor-like specificities (TCR-like mAbs) provide a means to target intracellular tumor- or virus-associated antigens by recognising their processed peptides presented on major histocompatibility complex (MHC) class I (pMHC) complexes. These antibodies are however thought to be relevant only for a single HLA allele. Here, we show that HLA-A*02:01-restricted EBV antigenic peptides EBNA1562-570, LMP1125-133and LMP2A426-434display binding degeneracy towards HLA-A*02 allelic microvariants, and that these pMHC complexes are recognised by anti-EBV TCR-like mAbs E1, L1 and L2 raised in the context of HLA-A*02:01. These antibodies bound endogenously derived pMHC targets on EBV–transformed human B lymphoblastoid cell lines expressing A*02:01, A*02:03, A*02:06 and A*02:07 alleles. More importantly, these TCR-like mAbs mediated both complement-dependent and antibody-dependent cellular cytotoxicity of these cell linesin vitro. This finding suggests the utility of TCR-like mAbs against target cells of closely related HLA subtypes, and the potential applicability of similar reagents within populations of diverse HLA-A*02 alleles.

16 August 2019 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
MWMona Meng Wang
Mona Meng Wang
WTWei Jian Tan
Wei Jian Tan
TLTong Seng Lim
Tong Seng Lim
Anita Sook Yee ChanAnita Sook Yee Chan
Anita Sook Yee Chan
Purpose: Vitreoretinal lymphoma (VRL) is a potentially fatal intraocular malignancy. Diagnosis is hampered by poor preservation of morphology and DNA/RNA integrity, which precludes adjunctive molecular analysis. We aimed to determine the optimum fixative protocol for VRL biopsies that permits cytology, IHC/flow cytometry and molecular analyses. Methods: Six fixatives were compared on cultured Pfeiffer cells used as a cellular model. Cells were fixed and evaluated on cellular morphology, antibody staining, DNA/RNA amount and integrity. VRL clinical cases were used as validation and proof-of-concept. Results: PreservCyt was the best fixative for preserving cellular morphology and high-quality RNA/DNA from vitreous fluid biopsies. Cells from clinical VRL cases fixed with PreservCyt showed adequate cellular morphology and IHC positivity. Sufficient DNA was obtained for IgH clonality and MYD88 mutation detection using remnant cytological fluid. Conclusions: PreservCyt maintains good morphology and RNA/DNA integrity suggesting that it is a suitable fixative for VRL diagnosis and molecular analysis.